Predictors of Unfavorable Pathology in Patients with Incidental (pT1a-T1b) Prostate Cancer.

Benign prostatic obstruction Incidental Predictor Prostate cancer Unfavorable pathology

Journal

European urology focus
ISSN: 2405-4569
Titre abrégé: Eur Urol Focus
Pays: Netherlands
ID NLM: 101665661

Informations de publication

Date de publication:
11 2022
Historique:
received: 13 12 2021
revised: 23 01 2022
accepted: 08 03 2022
pubmed: 24 3 2022
medline: 15 12 2022
entrez: 23 3 2022
Statut: ppublish

Résumé

Incidental prostate cancer (IPCa) is encountered in 10% of surgical procedures for benign prostatic obstruction (BPO). Identification of patients with underlying detrimental prostate cancer is paramount for tailored treatment decision-making, but guideline recommendations for this setting are lacking. To highlight clinical and histological characteristics related to BPO surgery that may predict IPCa with unfavorable pathology. We included men with IPCa who underwent radical prostatectomy (RP) in the short term after IPCa diagnosis. Two cohorts were built according to final pathology for the RP specimen: unfavorable pathology (International Society of Urological Pathology [ISUP] grade group [GG] ≥3 and/or ≥pT3a and/or pN1) versus favorable pathology. We performed multivariate regression analysis for the endpoint, which was unfavorable pathology for the RP specimen. Using the model estimates for prostate-specific antigen (PSA), ISUP GG, age, and prostate volume, we established a model for estimating the risk of unfavorable histopathology. Overall, 112 patients were included in the final assessment. On multivariate analysis, PSA (odds ratio [OR] 1.083, 95% confidence interval [CI] 1.003-1.170; p = 0.042), ISUP GG for the specimen from BPO surgery (OR 3.090; 95% CI 1.129-8.457; p = 0.028), and age (OR 1.121, 95% CI 1.026-1.225; p = 0.012) were independent predictors for unfavorable histopathology. On receiver operating characteristic analysis, the area under the curve was 0.751. A novel calculator was developed to predict adverse pathology for men with IPCa. The study is limited by its retrospective design. For men with IPCa, PSA before surgery for BPO, ISUP GG, and age are independent predictors of unfavorable disease. Our results might improve preoperative risk assessment for patient counseling. We developed a novel calculator to estimate the risk of underlying detrimental disease in men diagnosed with prostate cancer at surgery for benign prostatic obstruction.

Sections du résumé

BACKGROUND
Incidental prostate cancer (IPCa) is encountered in 10% of surgical procedures for benign prostatic obstruction (BPO). Identification of patients with underlying detrimental prostate cancer is paramount for tailored treatment decision-making, but guideline recommendations for this setting are lacking.
OBJECTIVE
To highlight clinical and histological characteristics related to BPO surgery that may predict IPCa with unfavorable pathology.
DESIGN, SETTING, AND PARTICIPANTS
We included men with IPCa who underwent radical prostatectomy (RP) in the short term after IPCa diagnosis. Two cohorts were built according to final pathology for the RP specimen: unfavorable pathology (International Society of Urological Pathology [ISUP] grade group [GG] ≥3 and/or ≥pT3a and/or pN1) versus favorable pathology.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS
We performed multivariate regression analysis for the endpoint, which was unfavorable pathology for the RP specimen. Using the model estimates for prostate-specific antigen (PSA), ISUP GG, age, and prostate volume, we established a model for estimating the risk of unfavorable histopathology.
RESULTS AND LIMITATIONS
Overall, 112 patients were included in the final assessment. On multivariate analysis, PSA (odds ratio [OR] 1.083, 95% confidence interval [CI] 1.003-1.170; p = 0.042), ISUP GG for the specimen from BPO surgery (OR 3.090; 95% CI 1.129-8.457; p = 0.028), and age (OR 1.121, 95% CI 1.026-1.225; p = 0.012) were independent predictors for unfavorable histopathology. On receiver operating characteristic analysis, the area under the curve was 0.751. A novel calculator was developed to predict adverse pathology for men with IPCa. The study is limited by its retrospective design.
CONCLUSIONS
For men with IPCa, PSA before surgery for BPO, ISUP GG, and age are independent predictors of unfavorable disease. Our results might improve preoperative risk assessment for patient counseling.
PATIENT SUMMARY
We developed a novel calculator to estimate the risk of underlying detrimental disease in men diagnosed with prostate cancer at surgery for benign prostatic obstruction.

Identifiants

pubmed: 35317972
pii: S2405-4569(22)00063-3
doi: 10.1016/j.euf.2022.03.009
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1599-1606

Informations de copyright

Copyright © 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Auteurs

Igor Tsaur (I)

Department of Urology and Pediatric Urology, University Medicine Mainz, Mainz, Germany. Electronic address: igor.tsaur@unimedizin-mainz.de.

Roderick C N van den Bergh (RCN)

Department of Urology, St Antonius Hospital, Utrecht, The Netherlands.

Timo Soeterik (T)

Department of Urology, St Antonius Hospital, Utrecht, The Netherlands.

Anita Thomas (A)

Department of Urology and Pediatric Urology, University Medicine Mainz, Mainz, Germany.

Maximilian P Brandt (MP)

Department of Urology and Pediatric Urology, University Medicine Mainz, Mainz, Germany.

Fabio Zattoni (F)

Department Surgery, Oncology and Gastroenterology, Urologic Unit, University of Padua, Padua, Italy.

Fabrizio Dal Moro (F)

Department Surgery, Oncology and Gastroenterology, Urologic Unit, University of Padua, Padua, Italy.

Alessandro Morlacco (A)

Department Surgery, Oncology and Gastroenterology, Urologic Unit, University of Padua, Padua, Italy.

Jeanlou Collavino (J)

Department Surgery, Oncology and Gastroenterology, Urologic Unit, University of Padua, Padua, Italy.

Guillaume Ploussard (G)

Department of Urology, La Croix du Sud Hospital, Toulouse, France; Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France.

Christian Surcel (C)

Center of Urologic Surgery, Dialysis and Renal Transplantation, Fundeni Clinical Institute, Bucharest, Romania.

Christian Mirvald (C)

Center of Urologic Surgery, Dialysis and Renal Transplantation, Fundeni Clinical Institute, Bucharest, Romania.

Orel Carmona (O)

Department of Urology, Chaim Sheba Medical Center, Tel Hashomer, Israel.

Barak Rosenzweig (B)

Department of Urology, Chaim Sheba Medical Center, Tel Hashomer, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Christian Ruckes (C)

Interdisciplinary Centre for Clinical Trials, University Medical Centre, Johannes Gutenberg University, Mainz, Germany.

Tatjana Heisinger (T)

Department of Urology, Medical University Innsbruck, Innsbruck, Austria.

Isabel Heidegger (I)

Department of Urology, Medical University Innsbruck, Innsbruck, Austria.

Giorgio Gandaglia (G)

Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.

Robert Dotzauer (R)

Department of Urology and Pediatric Urology, University Medicine Mainz, Mainz, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH